First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405-Reference-Cited by-同舟云学术

First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405

Published:2015-09-15 Issue:11 Volume:16 Page:
ISSN:1527-2729
Container-title:Current Treatment Options in Oncology
language:en
Short-container-title:Curr. Treat. Options in Oncol.

Author:

Elez Elena,Argilés Guillem,Tabernero Josep

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11864-015-0369-x.pdf

Reference32 articles.

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA: Cancer J Clin. 2012;62(4):220–41.

2. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.

3. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol : Off J Am Soc Clin Oncol. 2008;26(12):2013–9.

4. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol : Off J Am Soc Clin Oncol. 2011;29(15):2011–9. The CRYSTAL trial granted the approval for prescribing FOLFIRI plus cetuximab in first metastatic chemotherapy line in RAS WT CRC.

5. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–34. The PRIME study constructed the necessary evidence for using FOLFOX plus panitumumab in first metastatic line in RAS WT patient. This trail was the first in considering as a pre-specified end point the analysis according KRAS exon 2 status.

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular profiling and patient selection for the multimodal approaches for patients with resectable colorectal liver metastases;Hepatobiliary Surgery and Nutrition;2024-04

2. Retrospective analysis of the impact of dose delay and reduction on outcomes of colorectal cancer patients treated with FOLFIRI‑based treatment;PeerJ;2023-09-12

3. Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity;Cancer Medicine;2022-10-29

4. Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy;Targeted Oncology;2022-05

5. Correlation between schistosomiasis and CD8+ T cell and stromal PD-L1 as well as the different prognostic role of CD8+ T cell and PD-L1 in schistosomal-associated colorectal cancer and non-schistosomal-associated colorectal cancer;World Journal of Surgical Oncology;2021-11-07